← Eichor
Condition: Advanced Endometrial Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Endometrial Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 · 16 location(s) · MacroGenics · NCT06730347ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Phase 2 · 1 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT06561308BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1 · 4 location(s) · Bio-Path Holdings, Inc. · NCT04196257A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Phase 2/Phase 3 · 83 location(s) · Kartos Therapeutics, Inc. · NCT05797831Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Phase N/A · 1 location(s) · Radboud University Medical Center · NCT03621904Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · ModeX Therapeutics, An OPKO Health Company · NCT06239194Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdH
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06253494Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Phase 3 · 17 location(s) · Hutchmed · NCT06584032A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/Phase 2 · 15 location(s) · Terremoto Biosciences Inc. · NCT07109726A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 · 6 location(s) · SEED Therapeutics, Inc. · NCT07197554A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel i
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092373A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07209449Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · 242 location(s) · National Cancer Institute (NCI) · NCT07198074A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Phase 1 · 7 location(s) · Epsilogen Ltd · NCT06547840A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Phase 1 · 31 location(s) · Eli Lilly and Company · NCT07114601CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05410717Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TRO
Phase 2 · 96 location(s) · AstraZeneca · NCT05489211First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Phase 1 · 14 location(s) · TORL Biotherapeutics, LLC · NCT05103683
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.